News Case study backs YolTech's AATD gene therapy A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
News Lila Sciences' $235m first round, and other biofinancings Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.